Litigation Details for SK Biopharmaceuticals Co., Ltd v. Aurobindo Pharma Limited (D. Del. 2024)

SK Biopharmaceuticals Co., Ltd v. Aurobindo Pharma Limited (D. Del. 2024)

Docket	1:24-cv-00718	Date Filed	2024-06-18
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To	Christopher J. Burke
Parties	AUROBINDO PHARMA LIMITED
Patents	11,654,133; 7,598,279
Attorneys	William B. Coblentz
Firms	Morris James LLP
Link to Docket	External link to docket

Details for SK Biopharmaceuticals Co., Ltd v. Aurobindo Pharma Limited (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-06-18				External link to document

Litigation summary and analysis for: SK Biopharmaceuticals Co., Ltd v. Aurobindo Pharma Limited (D. Del. 2024)

Last updated: May 2, 2026

Litigation Summary and Patent-Focused Analysis: SK Biopharmaceuticals Co., Ltd v. Aurobindo Pharma Limited (1:24-cv-00718)

What is the case and what stage is it in?

SK Biopharmaceuticals Co., Ltd filed suit against Aurobindo Pharma Limited in the U.S. District Court for the District of Delaware under the Hatch-Waxman framework, alleging infringement of specified SK Biopharmaceuticals patents tied to an FDA-approved or FDA-action product. The docket number is 1:24-cv-00718. The litigation is at the early pleading stage, with the operative allegations centered on whether Aurobindo’s proposed product infringes SK’s listed claims and whether any asserted defenses (including non-infringement and invalidity) apply.

Case ID: SK Biopharmaceuticals Co., Ltd v. Aurobindo Pharma Limited
Court / Docket: D. Delaware, 1:24-cv-00718
Filing year: 2024
Proceeding type: Hatch-Waxman patent infringement litigation (BPCIA-style patent dispute framework adapted to CDER generics)

What patents and product linkages are asserted?

The case record for 1:24-cv-00718 identifies SK Biopharmaceuticals patents asserted against Aurobindo’s generic launch plans. In Hatch-Waxman, the asserted patents typically map to one of three categories: (1) active ingredient(s) composition claims, (2) formulation and/or manufacturing process claims, and (3) method-of-use and dosing regimen claims tied to label indications.

This dispute is organized around the common Hatch-Waxman infringement analysis:

• Claim chart construction: SK matches claim limitations to Aurobindo’s proposed generic product description from its FDA filing record.
• Infringement theory: SK alleges that Aurobindo’s product practices at least one asserted claim element-for-element, either literally or under the doctrine of equivalents.
• Response posture: Aurobindo contests infringement and raises validity defenses against the asserted claims.

What are the core infringement and validity issues likely contested?

Without relying on speculation about specific claim language, the standard structure for Delaware Hatch-Waxman disputes gives a predictable set of contested issues. Those issues generally fall into the same technical buckets:

1. Direct infringement vs. non-infringement

   • If SK asserts composition or formulation claims, the fight centers on whether the proposed generic product’s composition matches the claimed boundaries (drug substance identity, salts, polymorphs if claimed, excipient selections, ratios, particle attributes if claimed).
   • If SK asserts process claims, infringement analysis centers on whether the proposed manufacturing method performs each claimed step.
   • If SK asserts method-of-use claims, infringement centers on whether the proposed label (indications and dosing) would induce infringement.

2. Validity defenses

   • Novelty / anticipation: whether a single prior art reference discloses every element of the asserted claim.
   • Obviousness: whether combinations of prior art would have rendered the claim obvious.
   • Indefiniteness: whether the claims define boundaries with sufficient clarity.
   • Written description / enablement: whether the patent specification supports the claim scope.
   • Statutory bars and priority: whether filing dates and priority claims survive.

3. Non-infringement and “design-around” narratives

   • For composition/formulation, generic manufacturers often argue differences in formulation composition, crystal form, or manufacturing parameters.
   • For method-of-use, generic manufacturers typically argue label design differences or carve-outs that prevent induced infringement.
   • For process claims, generic manufacturers often argue that their actual process differs and that the proposed product description does not establish each process step.

How do Hatch-Waxman procedure and timelines shape leverage in this case?

In U.S. Hatch-Waxman actions, procedural timing drives settlement pressure and strategic choices. Typical decision points affecting leverage include:

• Initial pleadings and infringement contentions: SK must plead infringement with sufficient detail to identify asserted claims and theories tied to the ANDA-specific product.
• Validity and non-infringement defenses: Aurobindo must respond with contesting theories aimed at invalidating claims and preventing infringement.
• Markman posture: When claim construction is disputed, courts often set a Markman schedule that can accelerate early narrowing of factual disputes.
• Discovery sequencing and expert reports: Technical disputes on formulation, stability, particle properties, and label-driven use cases are usually expert-driven.
• Potential early dispositive motions: Motions under Rule 12 or summary judgment can compress the schedule if the court resolves claim scope against the patentee.

In practice, these procedural levers determine settlement windows, particularly when:

• The court’s claim construction preferences reduce the patentee’s ability to read on the accused product, or
• Prior art sets up an obviousness narrative strong enough to force the patentee into settlement.

What is the likely economic and commercial impact of this dispute?

Hatch-Waxman patent disputes are directly tied to:

• Entry timing: The generic’s FDA approval and launch schedule can be blocked or delayed based on the litigation outcome and applicable statutory stays.
• Design-around cost: Where claims target formulation or process, the generic may need line changes that increase cost and risk (and can still fail if equivalents remain broad).
• Market value of the authorized generic and launch sequencing: Settlement can reallocate market share and time to entry even if the patent does not ultimately get invalidated.

Given that SK Biopharmaceuticals is the plaintiff and Aurobindo Pharma is the defendant in 1:24-cv-00718, the dispute is structured to determine whether Aurobindo can launch its ANDA product without infringement liability tied to SK’s asserted patents.

What should business teams watch for in this docket?

This case’s decision path will likely hinge on a small number of events that signal whether SK can preserve enforceable scope through claim construction and trial readiness:

• Operative infringement contentions and claim chart specifics: Whether SK pins infringement on composition, formulation, process, or method-of-use elements.
• Claim construction briefs and the court’s Markman orders: Whether terms tied to boundaries (e.g., particle properties, crystalline forms, excipient selections, dosing timing) get narrowed.
• Expert reports addressing product equivalency: Whether Aurobindo can rebut element-by-element mapping from SK’s claim chart.
• Invalidity theory choice: Whether Aurobindo’s invalidity is anticipation-heavy or obviousness-heavy; which references are used; and whether the references are closer to commercial formulations.
• Settlement posture signs: Voluntary stipulations, narrowing amendments, and joint scheduling motions often precede resolution.

Comparative litigation posture: where these cases usually break

Across Hatch-Waxman suits in Delaware, resolution often follows one of these patterns:

• Early claim construction narrows to non-read: Aurobindo’s product avoids one critical limitation, which undercuts infringement or changes the doctrine-of-equivalents posture.
• Patent survivability fight: If Aurobindo’s prior art case is strong, settlement can still occur even without a final invalidation finding.
• Method-of-use label carve-outs: If the asserted claims are method-of-use, design-around via label changes can be decisive if supported by the proposed labeling.
• Process claim difficulty: Process claims are harder to prove from product description alone, so discovery often focuses on manufacturing records or expert inference.

The outcome in 1:24-cv-00718 will likely reflect whichever category dominates SK’s infringement theory in the asserted claims.

---

Key Takeaways

• Case: SK Biopharmaceuticals Co., Ltd v. Aurobindo Pharma Limited, 1:24-cv-00718 in the District of Delaware.
• Framework: Hatch-Waxman patent infringement litigation with early stage disputes over infringement and validity.
• Decision drivers: Claim construction, the element-by-element mapping of the accused product, and the strength of the anticipated prior art and obviousness arguments.
• Commercial lever: The litigation outcome influences market entry timing and the cost and feasibility of any generic design-around strategy.

---

FAQs

What is the docket number for SK Biopharmaceuticals v. Aurobindo?

1:24-cv-00718.

What court is handling the case?

The U.S. District Court for the District of Delaware.

Is this a patent infringement case under Hatch-Waxman?

Yes. The dispute aligns with Hatch-Waxman patent infringement litigation over an ANDA-linked product launch.

What issues typically determine outcomes in these cases?

Claim construction, whether the accused product meets every asserted claim element (or equivalence), and the strength of invalidity defenses like anticipation and obviousness.

What events in the docket most affect settlement leverage?

Markman/claim construction outcomes, expert report content on infringement mapping and prior art, and any early dispositive motion posture that narrows the case.

---

References

[1] U.S. District Court for the District of Delaware, Docket: SK Biopharmaceuticals Co., Ltd v. Aurobindo Pharma Limited, 1:24-cv-00718.